Wall Street analysts expect Masimo (NASDAQ:MASI) to post earnings of $0.73 per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Masimo’s earnings. The highest EPS estimate is $0.76 and the lowest is $0.70. Masimo posted earnings per share of $0.83 in the same quarter last year, which would indicate a negative year-over-year growth rate of 12%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 1st.
On average, analysts expect that Masimo will report full year earnings of $2.88 per share for the current year. For the next fiscal year, analysts anticipate that the business will report earnings of $2.98 per share, with EPS estimates ranging from $2.92 to $3.03. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that cover Masimo.
Masimo (NASDAQ:MASI) last released its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.06. The firm had revenue of $212.90 million for the quarter, compared to analysts’ expectations of $205.65 million. Masimo had a net margin of 15.99% and a return on equity of 23.14%. Masimo’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $0.57 EPS.
MASI has been the topic of several research analyst reports. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 7th. BidaskClub raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Piper Jaffray Companies reissued a “hold” rating and set a $91.00 target price on shares of Masimo in a research note on Thursday, March 1st. Barclays initiated coverage on shares of Masimo in a research note on Friday, March 9th. They set an “overweight” rating and a $97.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $100.00 target price on shares of Masimo in a research note on Thursday, May 3rd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $101.17.
Masimo stock opened at $99.12 on Wednesday. The stock has a market cap of $5.13 billion, a price-to-earnings ratio of 40.46, a P/E/G ratio of 2.36 and a beta of 0.95. Masimo has a 52 week low of $80.69 and a 52 week high of $100.00.
In other news, insider Jon Coleman sold 29,303 shares of Masimo stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $87.50, for a total value of $2,564,012.50. Following the transaction, the insider now owns 20,504 shares of the company’s stock, valued at approximately $1,794,100. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Ramshorst David J. Van sold 3,000 shares of Masimo stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of $97.50, for a total transaction of $292,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 2,500 shares in the company, valued at approximately $243,750. The disclosure for this sale can be found here. Insiders sold a total of 122,303 shares of company stock worth $11,148,690 in the last ninety days. Corporate insiders own 12.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in MASI. USA Mutuals Advisors Inc. acquired a new position in shares of Masimo in the 4th quarter worth approximately $110,000. SeaCrest Wealth Management LLC acquired a new position in shares of Masimo in the 4th quarter worth approximately $116,000. Advisors Preferred LLC acquired a new position in shares of Masimo in the 4th quarter worth approximately $158,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Masimo in the 1st quarter worth approximately $202,000. Finally, Neuberger Berman Group LLC acquired a new position in shares of Masimo in the 1st quarter worth approximately $203,000. 82.92% of the stock is currently owned by institutional investors.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.